
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
National report - Many skin conditions are a manifestation of an insult to the skin barrier, so an awareness of that barrier, what affects it and how, is imperative for a physician to effectively manage his or her dermatologic patients.